Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
about
Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in ChildrenAdvances in predicting acute GVHDEvaluation of published single nucleotide polymorphisms associated with acute GVHDIdentification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group.ABCB1 C3435T polymorphism is associated with leukemia susceptibility: evidence from a meta-analysisThe Impact of Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Methotrexate ProphylaxisHigher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descentCD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantationCytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for LymphomaGenetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignanciesCyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.The association between polymorphisms in the MDR1 gene and risk of cancer: a systematic review and pooled analysis of 52 case-control studies.The major histocompatibility complex: a model for understanding graft-versus-host disease.Novel application of lentiviral vectors towards treatment of graft-versus-host disease.Immunoregulatory gene polymorphisms and graft-versus-host disease.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Genomic studies of GVHD-lessons learned thus far.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation.Immunology of hematopoietic stem cell transplant.An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation.Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes.The Incidence of and Factors Associated with Vitamin D Deficiency in Newly Diagnosed Children with Cancer.From genetic single candidate gene studies to complex genomics of GvHD.Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.PharmGKB summary: very important pharmacogene information for CYP2B6.Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study.Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.Distinctiveness of the Roma population within CYP2B6 worldwide variation.Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation.The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
P2860
Q26798470-076D1569-1040-48ED-B599-7F8F0C345E82Q27021123-1F310772-241F-40E4-B7B4-DF36435C805BQ27026616-2BFCF9B0-BBB8-4981-956D-47953CC8E251Q28080914-D9904737-049A-4D5C-95DB-5B605DC7ED99Q33646358-9B7765F6-4E25-4446-9B29-EAE518794174Q33874148-D4A57644-F501-4DA4-AEDD-B0947E68D176Q34026161-F1F1AA0B-3623-4586-AC4C-507FC3F21E8FQ34812985-49765782-E1F8-4100-A8CE-38BACC4CEB03Q35593505-947EDFE5-E7EB-4D1B-9B67-B31DEB2E4D7AQ36175130-A93A2DA0-6F26-4E66-BF5A-F884AC7A2B06Q36384257-4777D0D7-9C90-4EC2-964E-F5E3A1AE5105Q36403184-7A4013D1-875A-4B41-9014-CA5F739A5F3BQ36634466-0D0C0033-D5FD-453B-AEF5-928C87DC6CF1Q36662017-06E9922B-11FA-456B-B95A-9F385F527FB4Q36715943-B4614411-EE44-4F96-9D3D-9226F9E1A56DQ36891521-4F07991F-DC6E-49F0-9442-642BAB5DA0A4Q37169090-EB6DF35D-BC9A-4B4E-9B94-593E091A4EFBQ37489887-9C3CAAB0-E615-4CB4-A541-2F5F1DF450ECQ37755281-A086DFF3-2163-4173-9413-3D1BBB9BD95DQ37939200-9110310F-6DE4-44E5-8656-8D44BF73BAB3Q37985519-D38A8206-B7CB-431A-AE56-B3A5DE5926D1Q38063197-4627FCD7-D8D8-4FDF-BAF6-A5A1F76732B3Q38068541-B3E2D77E-714C-4894-B04F-3BC4A2DA70C9Q38258161-1B423B72-C55E-4E94-AE68-9ACBF74D8D10Q38372455-EBFD7402-1D6A-4354-A1D0-4F16409D5AD7Q38623211-2C596994-F696-4AE1-A0E5-4731161C4B94Q38764044-E5B929B2-32CE-4336-8AB1-0FF05811E2EFQ38857203-65A0DB15-61BC-45AA-85BC-2BEFA0EE264EQ39263959-620C01C7-3E7D-4A65-A010-1B3906D293EFQ40498649-4B441A99-68CA-40C3-93BC-B45F6B935FB9Q42725538-FD752B6F-3F48-4C79-A5B0-A8B0E7329EE6Q43067189-DFFC18B7-F07C-4CE4-98B5-DE1393E53E90Q43429437-86F6E539-6383-4C33-8E75-B448301C0C1AQ45192061-3442FEDE-706E-48C5-A658-E461564010FEQ47670434-53B00B91-2B35-491A-A8A4-F89E92C14C2BQ50802622-38F0F6B7-1B4B-4500-B568-D0820E65FB9CQ54187733-971F7755-9EE6-4C45-95F8-46DEB3A362F9Q54686050-3323C709-09F1-4D9A-9802-FC57BA3CB838
P2860
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Association of drug metabolism ...... on for patients with leukemia.
@en
Association of drug metabolism ...... on for patients with leukemia.
@nl
type
label
Association of drug metabolism ...... on for patients with leukemia.
@en
Association of drug metabolism ...... on for patients with leukemia.
@nl
prefLabel
Association of drug metabolism ...... on for patients with leukemia.
@en
Association of drug metabolism ...... on for patients with leukemia.
@nl
P2093
P2860
P921
P356
P1433
P1476
Association of drug metabolism ...... on for patients with leukemia.
@en
P2093
A Devergie
D L Zanette
E Gluckman
H Bittencourt
J F Fernandes
J Larghero
P2860
P2888
P304
P356
10.1038/LEU.2008.323
P577
2008-11-13T00:00:00Z